Becton, Dickinson and Company (BD) has of $407m in the third quarter (Q3) of 2023, a rise of 13% compared with $360m in the year-ago period.
For the quarter that ended on 30 June 2023, the company鈥檚 revenues were $4.8bn against $4.6bn in the same quarter last year, representing an increase of 5.1%.
In the quarter, the company’s reported diluted earnings per share (EPS) stood at $1.36, while the adjusted EPS was at $2.96.
For nine months that ended on 30 June 2023, the company reported a net income of $1.37bn, a decline of 7.7% compared with $1.49bn in the prior year’s quarter.
Total revenues from continuing operations during this period were reported to be $14.2bn against $14.1bn in the prior year.
BD chairman, CEO and president Tom Polen said: 鈥淥ur teams are working unwaveringly to achieve key milestones that set us up for continued growth and consistent performance.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData鈥淲e are very pleased to deliver our number one priority since launching BD 2025 鈥� achieving 510(k) clearance for the updated BD Alaris Infusion System 鈥� allowing us to bring this updated system to our customers and their patients.鈥�
Recently, BD concluded the divestment of its Surgical Instrumentation platform to STERIS for $540m.
The company anticipates that its revenues for fiscal year 2023 will be roughly $19.3bn, in comparison to the previously stated range of $19.2bn to $19.3bn.
The projected adjusted diluted EPS for the company’s fiscal year 2023, ranging from $12.10 to $12.32, remains the same.
However, this outlook accounts for a $0.02 reduction due to the divestiture of the Surgical Instrumentation platform and a $0.05 decrease resulting from recent foreign currency rates.
